• relapsed/refractory acute myeloid leukemia (aml) pipeline 2025: pioneering clinical developments by 50+ global leaders – delveinsi... Barchart.com Mon, 29 Sep 2025 17:42:26 GMT
• Relapsed/refractory acute myeloid leukemia (AML) Pipeline 2025: Pioneering Clinical Developments by 50+ Global Leaders – DelveInsi... Barchart.com Fri, 26 Sep 2025 14:52:00 GMT
• BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? Yahoo Finance Tue, 23 Sep 2025 07:00:00 GMT
• taiho oncology and cullinan therapeutics announce acceptance of abstracts for zipalertinib at the iaslc 2025 world conference on l... Nasdaq Mon, 15 Sep 2025 16:16:44 GMT
• H.C. Wainwright reiterates Buy rating on Cullinan Oncology stock at $24 Investing.com Fri, 12 Sep 2025 07:00:00 GMT
• Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum The Globe and Mail Fri, 12 Sep 2025 07:00:00 GMT
• leading biotech cullinan therapeutics to share targeted therapy pipeline at stifel 2025 immunology forum Stock Titan Fri, 12 Sep 2025 07:00:00 GMT
• cullinan therapeutics to participate in upcoming investor conferences 富途牛牛 Thu, 11 Sep 2025 19:28:36 GMT
• transcript : cullinan therapeutics, inc. presents at morgan stanley 23rd annual global healthcare conference, sep-10-2025 08 MarketScreener Wed, 10 Sep 2025 13:51:17 GMT
• Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer PR Newswire Tue, 09 Sep 2025 07:00:00 GMT
• 27.4% Response Rate: Zipalertinib Shows Promise for Hard-to-Treat Lung Cancer with EGFR Mutations Stock Titan Tue, 09 Sep 2025 07:00:00 GMT
• h.c. wainwright reiterates buy rating on cullinan oncology stock at $24 Investing.com Fri, 05 Sep 2025 07:00:00 GMT
• critical review: cullinan therapeutics (nasdaq:cgem) versus soligenix (nasdaq:sngx) Defense World Tue, 26 Aug 2025 07:00:00 GMT
• cullinan therapeutics to participate in upcoming investor conferences The Manila Times Fri, 22 Aug 2025 07:00:00 GMT
• Cullinan Oncology stock gets Buy rating from H.C. Wainwright ahead of WCLC data Investing.com Thu, 21 Aug 2025 07:00:00 GMT
• Cullinan Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire Thu, 21 Aug 2025 07:00:00 GMT
• biotech leader cullinan therapeutics sets stage for key updates at global healthcare conferences Stock Titan Thu, 21 Aug 2025 07:00:00 GMT
• cytokine market accelerates with immuno-oncology pipeline & openPR.com Tue, 12 Aug 2025 21:54:00 GMT
• egfr non-small cell lung cancer clinical trials, companies, therapeutic assessment, therapies, treatment algorithm, pipeline analy... Barchart.com Tue, 12 Aug 2025 07:00:00 GMT
• egfr non-small cell lung cancer clinical trials, companies, therapeutic assessment, therapies, treatment algorithm, pipeline analy... Barchart.com Mon, 11 Aug 2025 19:41:00 GMT
• william blair has pessimistic outlook of cgem q3 earnings Defense World Mon, 11 Aug 2025 09:55:40 GMT
• cullinan therapeutics (cgem) to release earnings on thursday Defense World Thu, 07 Aug 2025 11:50:36 GMT
• Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results GlobeNewswire Thu, 07 Aug 2025 07:00:00 GMT
• cullinan therapeutics announces phase 1 enrollment for cln-978 and strategic board appointments amid positive financial results Quiver Quantitative Thu, 07 Aug 2025 07:00:00 GMT
• cullinan therapeutics expands autoimmune pipeline with $510m war chest, multiple trial updates Stock Titan Thu, 07 Aug 2025 07:00:00 GMT
• cullinan therapeutics, inc. (nasdaq:cgem) given consensus rating of “buy” by brokerages Defense World Sun, 03 Aug 2025 12:55:07 GMT
• cullinan therapeutics to present updated zipalertinib data at iaslc 2025 world conference on lung cancer MSN Fri, 01 Aug 2025 10:28:10 GMT
• cullinan therapeutics to present updated zipalertinib data at iaslc 2025 world conference on lung cancer Yahoo Finance Thu, 31 Jul 2025 07:00:00 GMT
• Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on L... PR Newswire Tue, 22 Jul 2025 07:00:00 GMT
• taiho oncology to present updated zipalertinib data in lung cancer Investing.com Tue, 22 Jul 2025 07:00:00 GMT
• breakthrough lung cancer treatment: zipalertinib trial results reveal new hope for hard-to-treat egfr mutations Stock Titan Tue, 22 Jul 2025 07:00:00 GMT
• cullinan therapeutics: betting on zipalertinib nda catalyst Seeking Alpha Wed, 16 Jul 2025 02:24:00 GMT
• Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst Seeking Alpha Tue, 15 Jul 2025 07:00:00 GMT
• cullinan therapeutics stock: betting on zipalertinib nda catalyst (nasdaq:cgem) Seeking Alpha Tue, 15 Jul 2025 07:00:00 GMT
• cullinan therapeutics: a biopharmaceutical company with a modality-agnostic approach to drug development AInvest Tue, 15 Jul 2025 07:00:00 GMT
• zipalertinib's nda submission: can cullinan therapeutics finally cash in on its breakthrough? AInvest Tue, 15 Jul 2025 07:00:00 GMT
• disc medicine appoints nadim ahmed to its board of directors The Manila Times Mon, 14 Jul 2025 07:00:00 GMT
• egfr + nsclc pipeline appears robust with 25+ key pharma companies actively working in the therapeutics segment | delveinsight The Globe and Mail Tue, 08 Jul 2025 07:00:00 GMT
• cullinan oncology stock rating reiterated at buy by clear street Investing.com Australia Fri, 04 Jul 2025 03:01:15 GMT
• Cullinan Oncology stock rating reiterated at Buy by Clear Street Investing.com Thu, 03 Jul 2025 07:00:00 GMT
• cullinan therapeutics, inc.(nasdaqgs: cgem) dropped from russell 3000 growth index MarketScreener Mon, 30 Jun 2025 07:05:28 GMT
• cullinan therapeutics, inc.(nasdaqgs:cgem) dropped from russell microcap growth index MarketScreener Mon, 30 Jun 2025 07:00:00 GMT
• cullinan oncology acquires genrix’s bispecific t cell engagers targeting bcma and cd19 for autoimmune disease therapies geneonline.com Fri, 20 Jun 2025 06:22:46 GMT
• cullinan oncology acquires genrix t cell engagers targeting bcma and cd19 for autoimmune disease therapies geneonline.com Wed, 18 Jun 2025 02:52:03 GMT
• cullinan deals $712m to test genrix bispecific tce in autoimmune BioWorld MedTech Tue, 17 Jun 2025 07:00:00 GMT
• cullinan oncology acquires genrix’s bispecific t cell engager therapies targeting bcma and cd19 for autoimmune disease research geneonline.com Mon, 16 Jun 2025 21:08:04 GMT
• cullinan oncology acquires genrix’s bispecific t cell engager therapies targeting bcma and cd19 for autoimmune disease treatment geneonline.com Sun, 15 Jun 2025 16:06:57 GMT
• cullinan oncology acquires genrix t cell engagers targeting bcma and cd19 for autoimmune disease therapies geneonline.com Sat, 14 Jun 2025 07:00:00 GMT
• when (cgem) moves investors should listen news.stocktradersdaily.com Fri, 13 Jun 2025 13:56:00 GMT
• cullinan oncology acquires genrix’s t cell engagers targeting bcma and cd19 for autoimmune disease therapies geneonline.com Fri, 13 Jun 2025 07:00:00 GMT
• cullinan deals $712m to test genrix bispecific tce in autoimmune BioWorld MedTech Thu, 12 Jun 2025 07:00:00 GMT
• cullinan oncology acquires genrix’s bispecific t cell engager therapies targeting bcma and cd19 for autoimmune disease research geneonline.com Thu, 12 Jun 2025 03:03:24 GMT
• Cullinan Oncology Acquires Genrix’s Bispecific T Cell Engager Therapies Targeting BCMA and CD19 for Autoimmune Disease Research geneonline.com Wed, 11 Jun 2025 07:00:00 GMT
• cullinan oncology acquires genrix t cell engagers targeting bcma and cd19 for autoimmune disease therapies geneonline.com Tue, 10 Jun 2025 07:00:00 GMT
• cullinan oncology partners with genrix to develop t cell engagers targeting bcma and cd19 for autoimmune diseases geneonline.com Mon, 09 Jun 2025 15:06:54 GMT
• the week in pharma: action, reaction and insight – week to june 6 The Pharma Letter Sun, 08 Jun 2025 07:00:00 GMT
• cullinan oncology acquires genrix’s bispecific t cell engager therapies targeting bcma and cd19 for autoimmune diseases geneonline.com Sat, 07 Jun 2025 14:07:24 GMT
• Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal BioPharma Dive Thu, 05 Jun 2025 07:00:00 GMT
• Cullinan Oncology Secures $712 Million Deal with Genrix for BCMA and CD19 Bispecific T Cell Engagers geneonline.com Thu, 05 Jun 2025 07:00:00 GMT
• cullinan pens $700m pact for bcma bispecific to pair with another autoimmune t-cell engager Fierce Biotech Thu, 05 Jun 2025 07:00:00 GMT
• transcript : cullinan therapeutics, inc. - special call MarketScreener Thu, 05 Jun 2025 03:05:21 GMT
• cullinan licenses rights to velinotamig from genrix bio for $20m upfront TipRanks Wed, 04 Jun 2025 20:43:15 GMT
• Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio fo... GlobeNewswire Wed, 04 Jun 2025 07:00:00 GMT
• cullinan's $712m deal brings revolutionary bcma t cell therapy to autoimmune disease treatment Stock Titan Wed, 04 Jun 2025 07:00:00 GMT
• transcript : cullinan therapeutics, inc. - special call MarketScreener Wed, 04 Jun 2025 07:00:00 GMT
• transcript : cullinan therapeutics, inc. - shareholder/analyst call marketscreener.com Mon, 02 Jun 2025 06:24:33 GMT
• cullinan therapeutics inc - taiho oncology and cullinan therapeutics publish positive rezilient1 trial results MarketScreener Sun, 01 Jun 2025 12:25:38 GMT
• Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology PR Newswire Sun, 01 Jun 2025 07:00:00 GMT
• cullinan therapeutics to host analyst and investor event at 2025 asco annual meeting and participate in jefferies 2025 global heal... Yahoo Finance Thu, 29 May 2025 07:00:00 GMT
• ASCO: Cullinan, Taiho unveil lung cancer data behind FDA application plans Fierce Biotech Thu, 22 May 2025 07:00:00 GMT
• taiho oncology presents data at the 2025 american society of clinical oncology annual meeting PR Newswire Thu, 22 May 2025 07:00:00 GMT
• cullinan therapeutics, taiho pharmaceutical, and taiho oncology announce positive results from rezilient1 trial of zipalertinib in... Nasdaq Thu, 22 May 2025 07:00:00 GMT
• (cgem) pivots trading plans and risk controls news.stocktradersdaily.com Wed, 21 May 2025 16:54:00 GMT
• ubs adjusts price target on cullinan therapeutics to $24 from $30, maintains buy rating marketscreener.com Mon, 12 May 2025 13:56:15 GMT
• when the price of (cgem) talks, people listen news.stocktradersdaily.com Sun, 11 May 2025 06:18:00 GMT
• cullinan therapeutics provides corporate update and reports first quarter 2025 financial results GlobeNewswire Fri, 09 May 2025 00:00:25 GMT
• Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results GlobeNewswire Thu, 08 May 2025 07:00:00 GMT
• cullinan oncology (cgem) projects financial runway through 2028 GuruFocus Thu, 08 May 2025 07:00:00 GMT
• cullinan therapeutics (cgem) advances autoimmune and oncology pr GuruFocus Thu, 08 May 2025 00:47:33 GMT
• Cullinan Therapeutics launches Sjögren’s disease study Investing.com Tue, 29 Apr 2025 07:00:00 GMT
• cullinan therapeutics to initiate us study of cln-978 for moderate to severe sjogren's disease marketscreener.com Tue, 29 Apr 2025 07:00:00 GMT
• Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung C... GlobeNewswire Wed, 23 Apr 2025 07:00:00 GMT
• cullinan therapeutics to present positive rezilient1 study results of zipalertinib for nsclc at 2025 asco annual meeting Quiver Quantitative Wed, 23 Apr 2025 07:00:00 GMT
• taiho oncology to share data in five presentations, including two oral presentations, at the 2025 american society of clinical onc... PR Newswire Wed, 23 Apr 2025 07:00:00 GMT
• cullinan therapeutics (cgem) to present promising lung cancer st GuruFocus Wed, 23 Apr 2025 07:00:00 GMT
• cullinan therapeutics receives approval from european medicines agency to initiate phase 1 trial of cln-978, a bispecific cd19 t c... GlobeNewswire Wed, 16 Apr 2025 07:00:00 GMT
• ema greenlights cullinan’s arthritis drug trial in europe by investing.com Investing.com India Wed, 16 Apr 2025 07:00:00 GMT
• learn to evaluate (cgem) using the charts news.stocktradersdaily.com Tue, 15 Apr 2025 12:08:00 GMT
• Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data Seeking Alpha Tue, 08 Apr 2025 07:00:00 GMT
• cullinan oncology stock hits 52-week low at $7.82 Investing.com Australia Tue, 01 Apr 2025 07:00:00 GMT
• cullinan oncology stock hits 52-week low at $7.82 by investing.com Investing.com Canada Mon, 31 Mar 2025 07:00:00 GMT
• (cgem) technical pivots with risk controls news.stocktradersdaily.com Sun, 09 Mar 2025 00:02:00 GMT
• (cgem) technical pivots with risk controls news.stocktradersdaily.com Sat, 08 Mar 2025 08:00:00 GMT
• cullinan therapeutics: promising pipeline and upcoming catalysts justify buy rating TipRanks Fri, 07 Mar 2025 12:29:44 GMT
• cullinan therapeutics’ chief medical officer sells $41,754 in stock Investing.com India Fri, 28 Feb 2025 08:00:00 GMT
• cullinan therapeutics reports 2024 financial results and updates TipRanks Fri, 28 Feb 2025 05:08:25 GMT
• cullinan therapeutics ceo sells $106,872 in stock by investing.com Investing.com Canada Fri, 28 Feb 2025 00:42:27 GMT
• cullinan therapeutics’ chief medical officer sells $41,754 in stock by investing.com Investing.com UK Thu, 27 Feb 2025 22:04:00 GMT
• Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire Thu, 27 Feb 2025 08:00:00 GMT
• Cullinan Therapeutics Reports Phase 1 Study Updates and Financial Results for Q4 2024 Nasdaq Thu, 27 Feb 2025 08:00:00 GMT
• cullinan therapeutics ceo sells $106,872 in stock by investing.com Investing.com Nigeria Thu, 27 Feb 2025 08:00:00 GMT
• brief-cullinan oncology q4 pretax profit usd -47.53 million TradingView Thu, 27 Feb 2025 08:00:00 GMT
• cullinan therapeutics' chief medical officer sells $41,754 in stock Investing.com Thu, 27 Feb 2025 08:00:00 GMT
• cullinan therapeutics reports 2024 financial results and updates TipRanks Thu, 27 Feb 2025 08:00:00 GMT
• financial review: cullinan therapeutics (nasdaq:cgem) and adaptimmune therapeutics (nasdaq:adap) Defense World Wed, 26 Feb 2025 08:00:00 GMT
• exclusive access: cullinan therapeutics leadership reveals strategy at elite healthcare forums StockTitan Mon, 24 Feb 2025 12:00:00 GMT
• cullinan therapeutics to participate in upcoming investor conferences GlobeNewswire Mon, 24 Feb 2025 08:00:00 GMT
• cullinan oncology stock hits 52-week low at $8.99 by investing.com Investing.com Canada Sat, 22 Feb 2025 06:36:34 GMT
• cullinan oncology, inc. management's discussion and analysis of financial condition and results of operations. (form 10-q) Marketscreener.com Sun, 16 Feb 2025 14:19:02 GMT
• cullinan ceo talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach Fierce Biotech Fri, 07 Feb 2025 08:00:00 GMT
• (cgem) pivots trading plans and risk controls news.stocktradersdaily.com Tue, 04 Feb 2025 08:00:00 GMT
• Otsuka and Cullinan chase Dizal | ApexOnco - Clinical Trials news and analysis Oncology Pipeline Thu, 30 Jan 2025 08:00:00 GMT
• mid-stage hit for novel lung cancer drug zipalertinib The Pharma Letter Thu, 30 Jan 2025 08:00:00 GMT
• cullinan therapeutics to participate in fireside chat at the guggenheim securities smid cap biotech conference GlobeNewswire Thu, 30 Jan 2025 08:00:00 GMT
• cullinan oncology stock target raised to $33 at h.c. wainwright Investing.com Thu, 30 Jan 2025 08:00:00 GMT
• cullinan therapeutics reveals next-gen pipeline details at major biotech conference StockTitan Thu, 30 Jan 2025 08:00:00 GMT
• cullinan therapeutics says zipalertinib trial met primary endpoint -january 29, 2025 at 04:38 am est Marketscreener.com Wed, 29 Jan 2025 09:38:08 GMT
• Cullinan plans approval application for lung cancer drug this year based on phase 2 win Fierce Biotech Wed, 29 Jan 2025 08:00:00 GMT
• cullinan, taiho eye h2 filing for zipalertinib after mid-stage lung cancer win firstwordpharma.com Wed, 29 Jan 2025 08:00:00 GMT
• zipalertinib meets primary orr end point in egfr exon 20 nsclc CancerNetwork Wed, 29 Jan 2025 08:00:00 GMT
• cullinan reveals update on rezilient1 trial data for zipalertinib in non-small cell lung cancer RTTNews Wed, 29 Jan 2025 08:00:00 GMT
• taiho pharmaceutical, taiho oncology, and cullinan therapeutics announce primary endpoint met in phase 2b trial of zipalertinib in... Financial Times Wed, 29 Jan 2025 00:03:24 GMT
• game-changing lung cancer drug shows promise: new hope for egfr mutation patients StockTitan Wed, 29 Jan 2025 00:02:26 GMT
• Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in... PR Newswire Tue, 28 Jan 2025 08:00:00 GMT
• reviewing repligen (nasdaq:rgen) and cullinan therapeutics (nasdaq:cgem) Defense World Thu, 23 Jan 2025 08:00:00 GMT
• immunology startup ouro sets out with $120m for drugs that reset the immune system MedCity News Fri, 10 Jan 2025 08:00:00 GMT
• Cullinan Therapeutics’ CLN-978 And Zipalertinib Look Promising In NSCLC (NASDAQ:CGEM) Seeking Alpha Thu, 09 Jan 2025 08:00:00 GMT
• cullinan therapeutics' chief scientific officer sells shares worth $50,040 by investing.com Investing.com Canada Wed, 08 Jan 2025 03:32:26 GMT
• cullinan therapeutics' chief scientific officer sells shares worth $50,040 Investing.com Tue, 07 Jan 2025 08:00:00 GMT
• financial comparison: genfit (nasdaq:gnft) vs. cullinan therapeutics (nasdaq:cgem) Defense World Mon, 30 Dec 2024 08:00:00 GMT
• cullinan therapeutics ceo sells shares worth $99,708 Investing.com India Sat, 28 Dec 2024 00:56:09 GMT
• egfr-non small cell lung cancer market predicted to see upsurge through 2032, highlights delveinsight | astrazeneca, j&j innovativ... The Globe and Mail Thu, 26 Dec 2024 08:00:00 GMT
• Cullinan Therapeutics chief scientific officer sells $53,547 in stock By Investing.com Investing.com Australia Sat, 21 Dec 2024 08:00:00 GMT
• cullinan therapeutics chief legal officer sells $39,729 in stock Investing.com India Sat, 21 Dec 2024 08:00:00 GMT
• cullinan therapeutics chief scientific officer sells $53,547 in stock Investing.com India Fri, 20 Dec 2024 22:18:49 GMT
• cullinan therapeutics chief legal officer sells $39,729 in stock Investing.com Fri, 20 Dec 2024 08:00:00 GMT
• the big rebrand: why these 4 biopharmas changed their name this year Pharma Voice Wed, 04 Dec 2024 08:00:00 GMT
• non-small cell lung cancer treatment market 2032: clinical trials, medication, prevalence, incidence, therapies, ema, pdma, fda ap... The Globe and Mail Thu, 21 Nov 2024 12:12:53 GMT
• cullinan therapeutics announces q3 2024 progress and outlook TipRanks Thu, 21 Nov 2024 04:26:46 GMT
• cgem - cullinan therapeutics, inc. latest stock news & market updates StockTitan Fri, 15 Nov 2024 11:48:30 GMT
• a clinician’s mindset driving new standards of care for lung cancer Massachusetts Biotechnology Council Thu, 14 Nov 2024 08:00:00 GMT
• cullinan advances lupus treatment with new clinical trial Investing.com Thu, 14 Nov 2024 08:00:00 GMT
• cullinan therapeutics' chief scientific officer sells $125,120 in stock Investing.com India Fri, 08 Nov 2024 19:15:36 GMT
• cullinan therapeutics provides corporate update and reports third quarter 2024 financial results GlobeNewswire Thu, 07 Nov 2024 08:00:00 GMT
• cullinan therapeutics' chief scientific officer sells $125,120 in stock Investing.com Thu, 07 Nov 2024 08:00:00 GMT
• cullinan therapeutics advances pipeline despite $40.6m loss; maintains $639m cash position StockTitan Thu, 07 Nov 2024 08:00:00 GMT
• cullinan therapeutics to participate in fireside chat at stifel 2024 healthcare conference GlobeNewswire Tue, 05 Nov 2024 12:05:40 GMT
• cullinan therapeutics ceo to present at stifel 2024 healthcare conference StockTitan Tue, 05 Nov 2024 08:00:00 GMT
• cullinan therapeutics to present preclinical data for cln-978, a cd19-directed t cell engager, at acr convergence 2024 GlobeNewswire Mon, 04 Nov 2024 08:00:00 GMT
• btig maintains $30 target on cullinan oncology shares by investing.com Investing.com UK Tue, 29 Oct 2024 07:00:00 GMT
• ubs sees upside in cullinan oncology stock as key trials approach Investing.com Thu, 24 Oct 2024 19:55:55 GMT
• cullinan oncology stock gets 5% price target increase, h.c. wainwright remains bullish after fda approval Investing.com UK Thu, 17 Oct 2024 07:00:00 GMT
• cullinan therapeutics gets fda approval for lupus treatment study Marketscreener.com Wed, 16 Oct 2024 11:47:22 GMT
• Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously ... GlobeNewswire Wed, 16 Oct 2024 07:00:00 GMT
• stocks flashing renewed technical strength: cullinan therapeutics Investor's Business Daily Wed, 25 Sep 2024 07:00:00 GMT
• cullinan oncology maintains buy rating from h.c. wainwright with steady price target Investing.com Canada Thu, 19 Sep 2024 07:02:49 GMT
• cullinan therapeutics commences phase 1 trial for lupus treatment Investing.com Wed, 18 Sep 2024 07:57:46 GMT
• cullinan oncology maintains buy rating from h.c. wainwright with steady price target Investing.com Wed, 18 Sep 2024 07:00:00 GMT
• cullinan therapeutics receives approval to initiate its GlobeNewswire Tue, 17 Sep 2024 07:00:00 GMT
• cullinan therapeutics commences phase 1 trial for lupus treatment by investing.com Investing.com Canada Tue, 17 Sep 2024 07:00:00 GMT
• cullinan oncology holds stock target with buy rating post-esmo Investing.com Tue, 17 Sep 2024 04:20:06 GMT
• cullinan therapeutics, inc. announces submission of investigational new drug application to u.s. food and drug administration for ... Marketscreener.com Mon, 16 Sep 2024 11:00:00 GMT
• cullinan therapeutics announces submission of investigational new drug application to u.s. food and drug administration for cln-97... GlobeNewswire Mon, 16 Sep 2024 07:00:00 GMT
• cullinan seeks fda nod for lupus treatment by investing.com Investing.com Canada Mon, 16 Sep 2024 07:00:00 GMT
• cullinan oncology's stock gets buy rating after trial data Investing.com Mon, 16 Sep 2024 07:00:00 GMT
• cullinan oncology holds stock target with buy rating post-esmo Investing.com Mon, 16 Sep 2024 07:00:00 GMT
• cullinan therapeutics presents positive updated data from GlobeNewswire Sat, 14 Sep 2024 07:00:00 GMT
• cullinan therapeutics (nasdaq:cgem) versus cargo therapeutics (nasdaq:crgx) head-to-head review Defense World Sat, 14 Sep 2024 07:00:00 GMT
• cullinan therapeutics: fundraising capability, emergence in autoimmune disease (cgem) Seeking Alpha Fri, 30 Aug 2024 07:00:00 GMT
• merck picks up novel bispecific antibody with potential in both cancer & autoimmune disease MedCity News Mon, 12 Aug 2024 07:00:00 GMT
• fierce pharma asia—the trop2 adc race; another merck-daiichi cancer deal; eisai's molecular glue pact FiercePharma Fri, 09 Aug 2024 07:00:00 GMT
• merck pays $700m for bispecific, spying autoimmune opening and chance to challenge amgen in cancer Fierce Biotech Fri, 09 Aug 2024 07:00:00 GMT
• morgan stanley cuts cullinan oncology target to $38on dissapointing results Investing.com Thu, 08 Aug 2024 17:55:44 GMT
• Cullinan hands back bispecific to Harbour BioMed a year after paying $25M for US rights Fierce Biotech Thu, 08 Aug 2024 07:00:00 GMT
• cullinan therapeutics provides corporate update and reports second quarter 2024 financial results GlobeNewswire Thu, 08 Aug 2024 07:00:00 GMT
• reviewing cullinan therapeutics (nasdaq:cgem) & neumora therapeutics (nasdaq:nmra) Defense World Sat, 03 Aug 2024 05:10:34 GMT
• financial comparison: cullinan therapeutics (nasdaq:cgem) vs. krystal biotech (nasdaq:krys) Defense World Sat, 03 Aug 2024 05:09:45 GMT
• why is cullinan therapeutics stock trading higher on wednesday? Yahoo Finance Thu, 01 Aug 2024 09:06:08 GMT
• cytokine market growing rapidly by 2031 - cullinan oncology inc, openPR Tue, 16 Jul 2024 07:00:00 GMT
• contrasting cullinan therapeutics (nasdaq:cgem) and dyadic international (nasdaq:dyai) American Banking and Market News Sun, 14 Jul 2024 07:00:00 GMT
• head-to-head analysis: cullinan therapeutics (nasdaq:cgem) versus twist bioscience (nasdaq:twst) Defense World Wed, 10 Jul 2024 05:26:13 GMT
• cullinan therapeutics publishes work leading to development of fusion protein cln-617 BioWorld MedTech Thu, 04 Jul 2024 07:00:00 GMT
• egfr non-small cell lung cancer clinical trial pipeline GlobeNewswire Wed, 03 Jul 2024 07:00:00 GMT
• cullinan therapeutics holds annual stockholder meeting by investing.com Investing.com India Fri, 28 Jun 2024 23:41:02 GMT
• aridis pharmaceuticals director buys $50,000 in company stock by investing.com Investing.com India Fri, 28 Jun 2024 23:41:02 GMT
• cullinan therapeutics holds annual stockholder meeting by investing.com Investing.com UK Thu, 27 Jun 2024 21:08:00 GMT
• palo alto networks director mccarthy sells over $312k in company stock by investing.com Investing.com UK Thu, 27 Jun 2024 21:08:00 GMT
• cgem - cullinan therapeutics, inc. latest stock news & market updates StockTitan Wed, 19 Jun 2024 17:33:06 GMT
• cgem - cullinan oncology, inc. latest stock news & market updates StockTitan Wed, 19 Jun 2024 17:33:06 GMT
• piper sandler trims hf sinclair shares target, cites financial outlook concerns by investing.com Investing.com Fri, 14 Jun 2024 07:00:00 GMT
• Cullinan Therapeutics announces success for zipalertinib as combo therapy Clinical Trials Arena Mon, 03 Jun 2024 07:00:00 GMT
• Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib GlobeNewswire Sat, 01 Jun 2024 07:00:00 GMT
• egfr inhibitors market to grow at a decent cagr during the study period (2020–2034) by delveinsight ... Barchart Fri, 31 May 2024 11:19:58 GMT
• cullinan therapeutics to participate in fireside chat at td cowen 5th annual oncology innovation summit Yahoo Finance Fri, 24 May 2024 07:00:00 GMT
• cullinan therapeutics to present first data for cln-619, a novel anti-mica/b antibody, in combination with a checkpoint inhibitor ... Investing News Network Thu, 23 May 2024 07:00:00 GMT
• beyond biotech podcast 15: cullinan oncology, pleco therapeutics, tikomed Labiotech.eu Thu, 23 May 2024 07:00:00 GMT
• cullinan oncology, inc. (nasdaq:cgem) forecasted to post q2 2024 earnings of ($0.74) per share MarketBeat Mon, 20 May 2024 19:17:50 GMT
• wedbush reaffirms “outperform” rating for cullinan oncology (nasdaq:cgem) Defense World Mon, 20 May 2024 09:20:31 GMT
• cullinan oncology, inc. (nasdaq:cgem) to post q2 2024 earnings of ($0.74) per share, hc wainwright forecasts Defense World Mon, 20 May 2024 07:05:28 GMT
• analysts set expectations for cullinan therapeutics, inc.'s q2 2024 earnings (nasdaq:cgem) MarketBeat Mon, 20 May 2024 07:00:00 GMT
• q2 2024 earnings estimate for cullinan oncology, inc. issued by wedbush (nasdaq:cgem) Defense World Mon, 20 May 2024 07:00:00 GMT
Cullinan Oncology, Inc(NASDAQ:CGEM) 
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalati...
Website: https://www.cullinanoncology.com/
Founded: 2016
CEO: Owen Hughes
Sector: Pharmaceuticals
Industry:
Share this website to your friends